Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · IEX Real-Time Price · USD
2.210
-0.080 (-3.49%)
At close: Jun 21, 2024, 4:00 PM
2.200
-0.010 (-0.45%)
After-hours: Jun 21, 2024, 7:59 PM EDT

Esperion Therapeutics Revenue

Esperion Therapeutics had revenue of $229.74M in the twelve months ending March 31, 2024, with 183.74% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $137.74M with 466.14% year-over-year growth. In the year 2023, Esperion Therapeutics had annual revenue of $116.33M with 54.14% growth.

Revenue (ttm)
$229.74M
Revenue Growth
+183.74%
P/S Ratio
1.64
Revenue / Employee
$957,250
Employees
240
Market Cap
376.62M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023116.33M40.86M54.14%
Dec 31, 202275.48M-2.97M-3.79%
Dec 31, 202178.45M-149.10M-65.52%
Dec 31, 2020227.55M79.18M53.37%
Dec 31, 2019148.36M--
Dec 31, 20180--
Dec 31, 20170--
Dec 31, 20160--
Dec 31, 20150--
Dec 31, 20140--
Dec 31, 20130--
Dec 31, 20120--
Dec 31, 20110--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Anika Therapeutics 169.26M
Alector 96.41M
Nano-X Imaging 10.01M
Precigen 5.44M
Fulcrum Therapeutics 2.51M
Revenue Rankings